**Divi's Labs** 

#### Q2FY25 Result Update

BUY

# Choice

Nov 10, 2024

CMP (Rs)	5,938
Target Price (Rs)	6.983
Potential Upside (%)	17.6
*CMP as on 8 <sup>th</sup> Nov 2024	

**Company Info** 

DIVI IN EQUITY
INE361B01024
2.0
6,276
3,350
1,576.4
18.7
265.5/48
69.2
136.7


#### Shareholding Pattern (%)

	Sep-24	Jun-24	Mar-24
Promoters	51.89	51.89	51.92
FII's	17.25	16.16	14.68
DII's	20.98	21.66	22.10
Public	9.88	10.27	11.29

#### **Relative Performance (%)**

YTD	3Y	2Y	1Y
BSE Healthcare	75.0	83.4	53.8
Divi's Labs	21.8	57.1	70.2

#### **Rebased Price Performance**



#### Deepika Murarka

Email: deepika.murarka@choiceindia.com Ph: +91 22 6707 9513

#### Maitri Sheth

Email: maitri.sheth@choiceindia.com Ph: +91 22 6707 9666

Divis Laboratories reported robust quarterly numbers which were above estimations. Revenue at INR 23,380mn was up 22.5% YoY and 10.4% QoQ, driven by growth in the Custom Synthesis business, which saw an increased demand from current and potential customers. The constant currency growth stood at 21%. EBITDA saw robust growth of 49.5% YoY and 15.1% QoQ to INR 7,160mn, with an EBITDA margin of 30.6%, expanding 553bps YoY and 126bps QoQ due to stability in the material costs. The product mix for generics to custom synthesis was reported at 49% and 51%. Exports for the quarter are

about 87%, and exports to the US and Europe are about 71%.

- Custom Synthesis (51% of revenue): The Custom Synthesis segment saw a significant growth of 56.2% YoY and 14.9% QoQ, due to increasing demand from existing and new potential customers. The company has also filed DMFs for several of its upcoming products that are coming off patent. In keeping with its strategic focus on developing this specialized portfolio, the company is also actively producing peptide building blocks. Divi's is strengthening its standing as a reliable partner in complex and valuable chemicals in addition to increasing its market share.
- Generic (49% of revenue): The generic saw a marginal decline of 2.4% YoY and growth of 1.7% QoQ, because of pricing pressure and industry-wide challenges, due expect it to stabilize in the near future. The overall impact on the generic business was mitigated by the continued success of the emerging generic product portfolio despite the market challenges. There are significant generic products in the future pipeline that are moving closer to regulatory approval and customer qualification in the US and Europe. Beginning in 2026, these future generic products will begin to contribute to revenue. This integration helps the company control impurity profiles, thereby avoiding regulatory issues in the future. Capacity expansions in different compounds are anticipated to propel this growth.
- Margin performance: Despite a reduction in the gross margin, the company's EBITDA margin increased by 126bps YoY, driven by a change in the product mix, stability in the raw material prices, and benefit from backward integration. The management expects geopolitical factors may impact the raw material prices but remains optimistic to improve margins going forward.
- Outlook & Valuation: We continue to have a positive view of Divi's Lab because of the following: 1) Backward integration and the normalization of raw material prices; 2) capacity expansion for the commercial supply of new products; 3) growth in the base business; and 4) major projects from large pharmaceutical companies are driving the growth in the custom synthesis business. We have introduced FY27E and valued the stock based on the SOTP valuation strategy on Sep-FY27E and arrived at a target price of INR 6,983 and recommend a BUY rating on the stock.

#### **Financial Snapshot**

Year end: March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Revenue (INR Mn.)	89,598	77,675	78,450	93,156	1,11,581	1,41,219
Gross Profit (INR Mn.)	59,927	47,138	47,160	55,902	68,747	87,384
EBITDA (INR Mn.)	38,820	23,636	22,050	27,955	36,388	47,136
EBITDA Margin (%)	43.3	30.4	28.1	30.0	32.6	33.4
EPS (INR)	111.5	68.7	60.3	78.6	103.8	136.7

Quarterly performance								
Rs. In Mn.	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)			
Revenue	23,380	19,090	22.5	21,180	10.4			
Cost of Goods Sold	9,690	8,100	19.6	8 <i>,</i> 530	13.6			
Gross Margin (%)	58.6	57.6	98 bps	59.7	(117) bps			
Employee Expenses	3,040	2,660	14.3	2,920	4.1			
EBITDA	7,160	4,790	49.5	6,220	15.1			
EBITDA Margin (%)	30.6	25.1	553 bps	29.4	126 bps			
Depreciation	990	950	4.2	970	2.1			
EBIT	6,170	3,840	60.7	5,250	17.5			
Interest	10	10	-	-	#DIV/0!			
PBT	7,220	4,690	53.9	6,040	19.5			
Tax	2,120	1,210	75.2	1,740	21.8			
Adj. PAT	5,100	3,480	46.6	4,300	18.6			
PAT Margin (%)	21.8	18.2	358 bps	20.3	151 bps			
Adj. EPS	19.2	13.1	46.6	16.2	18.6			

Source: Company, CEBPL

# **Segmental Performance**

Rs. In Mn.	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)
Generic Sales	9,176	9,404	(2.4)	9,022	1.7
% of sales	39.2	49.3		42.6	
Nutraceuticals	2,280	2,050	11.2	1,780	28.1
% of sales	9.8	10.7		8.4	
Custom Synthesis	11,924	7,636	56.2	10,378	14.9
% of sales	51.0	40.0		49.0	
Total Sales	23,380	19,090	22.5	21,180	10.4

Source: Company, CEBPL

## **Estimates vs Actual**

Particulars (Rs mn)	Actual	<b>CEBPL Estimates</b>	% Change
Net Sales	23,380	22,170	5.5
EBIDTA	7,160	6,385	12.1
EBIDTA Margin (%)	30.6	28.8	182.2
РАТ	5,100	4,549	12.1
EPS	19	17	12.1


Source: Company, CEBPL

# Changes in Estimates for FY25E & FY26E

Income Statement	FY25E			FY26E			FY27E
(INR Mn.)	New	Previous	Change	New	Previous	Change	New
Net sales	93,156	89,410	4.2	1,11,581	1,06,154	5.1	1,41,219
EBITDA	27,955	26,869	4.0	36,388	34,679	4.9	47,136
EBITDA margin(%)	30.0	30.1	(4) bps	32.6	32.7	(6) bps	33.4
РАТ	20,868	19,726	5.8	27,550	25,718	7.1	36,284
EPS	78.6	74.3	5.8	103.8	96.9	7.1	136.7

## **Management Call - Highlights**

- The strategy to diversify across portfolios is yielding positive results, with previous investments and expansions now showing their impact.
- While facing pricing pressures in generic markets due to industry challenges, optimism remains for market stabilization. Emerging generics continue to perform well, supporting overall momentum.
- A robust pipeline of generic products is advancing towards customer qualifications and regulatory approvals in the U.S. and Europe.
- The contrast media segment is progressing, with key customer engagements driving projects from qualifications to commercial supplies, signaling growth potential.
- Increased interest in custom synthesis from customers is evident, with more RSPs and onsite visits, aiming to build long-term partnerships emphasizing supply chain resilience and backward integration.
- Investments are being made in response to demand for peptide drugs targeting GLP-1, with expansions in solid-phase peptide synthesis and infrastructure. Multiple 500-liter reactors are operational, with plans for further expansion.
- Continuous flow chemistry technology is being successfully scaled from lab and pilot stages to commercial production over the next one to two years, enhancing efficiency and driving innovation.
- Greenfield expansion at Unit 3, a 200-acre project, is on track with phased production starting in December 2024, supporting growth and extending production capabilities.
- Divis is actively involved in both solid-phase and liquid-phase peptide synthesis for custom projects, manufacturing specific peptide chains based on customer requests.
- Shipping disruptions in the Red Sea have led to extended times and rerouting through South Africa; shipments were advanced, and safety stock levels were built to mitigate delays.
- A pipeline of generics coming off-patent in 2026 is being prepared, pending customer approvals and regulatory processes. Growth in contrast media volume is projected to increase 20%-30% YoY.



Generic Sales (Rs. mn) and QoQ Growth (%)

Source: Company, CEBPL

25000


22500

20000

17500

15000

#### Custom Synthesis (Rs. mn) and QoQ Growth (%)



Source: Company, CEBPL

10.4 30

25

20

15

10

5

0 -5

-10


-15

-20


23380

Q2FY25

#### Gross Profit (Rs. mn) and Margin (%)



Source: Company, CEBPL




## EBITDA (Rs. mn) and Margin (%)

Source: Company, CEBPL

Source: Company, CEBPL

# PAT (Rs. mn) and Margin (%)



Source: Company, CEBPL

Revenue (Rs. mn) and QoQ Growth (%)

(8.9)

17780

Q1FY24

7.4

19090

Q2FY24

14.2

19508

Q4FY23

Revenue (Rs. Mn.)

(7.9)

Q3FY23

(17.7)

18545

**Q2FY23** 

24.2

23030

Q4FY24

QoQ Growth (%) - RHS

(2.8)

18550


Q3FY24

(8.0)

21180


Q1FY25

#### Revenue (Rs. mn) and YoY Growth (%)




Source: Company, CEBPL






EBITDA (Rs. mn) and Margin (%)



Source: Company, CEBPL


# ROE (%) and ROIC (%)



Source: Company, CEBPL

Source: Company, CEBPL

#### **EV/EBITDA Band**



Source: Company, CEBPL

#### **SOTP Based Valuation**

Particulars	Amount (Rs. Mn.)	Allotted Multiple (x)	Value (in Rs. Mn)
Segmental EBITDA (Sep-FY27E)			
Generic API	4,114	25.00	1,02,852
Custom Synthesis	36,595	46.00	16,83,355
Nutraceuticals	1,053	25.00	26,335
Enterprise Value			18,12,542
Net Debt (Sep-FY27E)			-41,059
Implied Market Cap.			18,53,601
No. of shares			265
Target Price (Rs.)			6,983

# Income statement (Consolidated in INR Mn.)

Particular	FY22	FY23	FY24	FY25E	FY26E	FY27E
Revenue	89,598	77,675	78,450	93,156	1,11,581	1,41,219
Gross profit	59,927	47,138	47,160	55,902	68,747	87,384
EBITDA	38,820	23,636	22,050	27,955	36,388	47,136
Depreciation	3,115	3,432	3,780	4,117	4,432	4,810
EBIT	35,705	20,204	18,270	23,838	31,956	42,326
Other income	1,139	3,489	3,390	4,006	4,798	6,072
Interest expense	8	7	30	20	20	20
РВТ	36,835	23,686	21,630	27,824	36,734	48,379
Adj. PAT	29,605	18,234	16,000	20,868	27,550	36,284
Adj. EPS (INR)	111.5	68.7	60.3	78.6	103.8	136.7


# Balance sheet (Consolidated in INR Mn.)

· · · · · · · · · · · · · · · · · · ·						
Particular	FY22	FY23	FY24	FY25E	FY26E	FY27E
Net worth	1,17,282	1,27,671	1,35,711	1,48,615	1,68,202	1,96,523
Borrowings	37	33	30	30	30	30
Trade Payables	7,957	7,625	8,240	9,698	10,700	13,542
Other current liabilities	3,990	3,381	4,530	5,866	6,105	7,706
Other non- current liabilities	4,481	5,678	6,190	4,932	3,223	3,282
Total Net Worth & liabilities	1,33,747	1,44,388	1,54,701	1,69,141	1,88,260	2,21,083
Net Block	43,141	47,142	47,330	58,213	63,781	68,971
Capital WIP	4,699	2,119	7,780	6,780	5,780	4,780
Goodwill & intangible assets	75	53	40	40	40	40
Investments	720	771	820	820	820	820
Trade Receivables	24,239	17,925	21,560	24,501	29,959	37,916
Cash & Cash equivalents	28,189	42,131	39,800	36,762	37,882	44,295
Other non-current assets	1,597	1,187	1,980	2,137	2,266	3,974
Other current assets	31,087	33,061	35,391	39,888	47,732	60,286
Total Assets	1,33,747	1,44,388	1,54,701	1,69,141	1,88,260	2,21,083
Cash Flows (INR Mn.)	FY22	FY23	FY24	FY25E	FY26E	FY27E
CFO	19,118	24,598	12,610	17,772	18,055	22,892
CFI	(21,943)	(27,076)	(5,721)	(13,679)	(8,995)	(8,995)
CFF	(5,325)	(7,972)	(7,999)	(7,130)	(7,940)	(7,485)

# Choice

	EV22	5//20	5)/2.4	EVALE	EVACE	EV075
Growth Ratios (%)	FY22	FY23	FY24	FY25E	FY26E	FY27E
Revenues	28.6	(13.3)	1.0	18.7	19.8	26.6
Gross Profit	29.0	(21.3)	0.0	18.5	23.0	27.1
EBITDA	35.7	(39.1)	(6.7)	26.8	30.2	29.5
EBIT	37.1	(43.4)	(9.6)	30.5	34.1	32.5
РВТ	38.2	(35.7)	(8.7)	28.6	32.0	31.7
Adj. PAT	49.2	(38.4)	(12.3)	30.4	32.0	31.7
Margins (%)						
Gross Profit	66.9	60.7	60.1	60.0	61.6	61.9
EBITDA	43.3	30.4	28.1	30.0	32.6	33.4
EBIT	39.8	26.0	23.3	25.6	28.6	30.0
РВТ	41.1	30.5	27.6	29.9	32.9	34.3
Tax rate	19.6	23.0	26.0	25.0	25.0	25.0
Adj. PAT	33.0	23.5	20.4	22.4	24.7	25.7
Profitability (%)						
ROE	25.2	14.3	11.8	14.0	16.4	18.5
ROIC	32.0	17.2	13.1	15.1	17.5	19.8
ROCE	30.4	15.8	13.5	16.0	19.0	21.5
Financial leverage (x)						
Pre-tax OCF/EBITDA	0.7	1.3	0.8	0.9	0.7	0.7
OCF / Net profit	0.6	1.3	0.8	0.9	0.7	0.6
EV/EBITDA	23.2	37.6	47.8	37.8	29.0	22.3
Earnings						
EPS (Rs.)	112	69	60	79	104	137
Shares outstanding	265	265	265	265	265	265
Working Capital (days)						
Inventory days (x)	115	141	148	140	140	140
Receivable days (x)	99	84	100	96	98	98
Creditor days (x)	32	36	38	38	35	35
Current Ratio (x)	7.0	8.5	7.6	6.5	6.9	6.7
Source: Company CERDI						

#### Historical recommendations and target price: Divi's Laboratories



Divi	's Laboratories		
1.	10-08-2021	ADD,	Target Price Rs.5,190
2.	12-11-2021	REDUCE,	Target Price Rs.4,513
3.	14-02-2022	ADD,	Target Price Rs.4,905
4.	25-05-2022	NEUTRAL,	Target Price Rs.3,860
5.	16-08-2022	ADD,	Target Price Rs.3,980
6.	09-11-2022	ADD,	Target Price Rs 3,668
7.	04-02-2023	NEUTRAL,	Target Price Rs.2,987
8.	21-05-2023	ADD,	Target Price Rs.3,458
9.	16-08-2023	NEUTRAL,	Target Price Rs.3,884
10.	07-11-2023	ADD,	Target Price Rs.3,932
11.	13-02-2024	ADD,	Target Price Rs.4,077
12.	27-05-2024	BUY,	Target Price Rs.4,767
13.	06-08-2024	BUY,	Target Price Rs.5,000
14.	10-11-2024	BUY,	Target Price Rs.6,983

Institutional Research T	eam		
Jathin kaithavalappil	AVP – Automobile /Defence/Real Estate	jathin.jayan@choiceindia,coM	+91 22 6707 9994
Deepika Murarka	Analyst - Pharmaceuticals / Healthcare	deepika.murarka@choiceindia.com	+91 22 6707 9513
Ashutosh Murarka	Analyst – Cement / Building Material	ashutosh.murarka@choiceindia.com	+91 22 6707 9442
Putta Ravi Kumar	Analyst – Defence	ravi.putta@choiceindia.com	+91 22 6707 9908
Aayush saboo	Associate – Real Estate	aayush.saboo@choiceindia.com	+91 22 6707 9811
Maitri Sheth	Analyst – Pharmaceuticals / Healthcare	maitri.sheth@choiceindia.com	+91 22 6707 9811
Bharat Kumar Kudikyala	Associate – Cement / Building Material	bharat.kudikyala@choiceindia.com	+91 22 6707 9798
Arshay Agarwal	Associate – BFSI	arshay.agarwal@choiceindia.com	+91 22 6707 9811
Heet Chheda	Associate – Automobile	heet.chheda@choiceindia.com	+91 22 6707 9422
Rushil Katiyar	Associate - Information Technology	Rushil.katiyar@choiceindia.com	+91 22 6707 9811
CA Sheetal Murarka	Vice President - Institutional Sales	sheetal.murarka@choiceindia.com	+91 22 6707 9857
Nitesh Jalan	AVP – Institutional Sales	nitesh.jalan@choiceindia.com	+91 22 6707 9877 /878 /879

#### **CHOICE RATING DISTRIBUTION & METHODOLOGY**

BUY

The security is expected to generate greater than or = 15% over the next 24 months

HOLD The security expected to show upside or downside returns by 14% to -5% overhead 24 months

SELL The security expected to show Below -5% next 24 months

#### Disclaimer

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited-Research Analyst - INH000000222. (CIN. NO.: U65999MH2010PTC198714). Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri(East), Mumbai 400099. Tel. No. 022-6707 9999

Compliance Officer--Prashant Salian, Email Id - Prashant.salain@choiceindia.com Contact no. 022- 67079999- Ext-2310

Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834. Email- ig@choiceindia.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL RE" Limited. The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include guality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person

placing reliance on the report to undertake trading does so entirely at his or her own risk and CEBPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General Disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment

/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide

for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own Study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Yester performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding

taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever. Find (Choice Equity Broking Pvt. Ltd.—Research Analyst] [NH CHB] | Capital IQ | Email: institutional.equities@choiceindia.com | Ph: +91 22 6707 9919

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" equires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this report.

#### Disclosures of Interest (Additional):

- 1. "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. "CEBPL" its research Analyst, or its associates or relatives of the research analyst
- affiliates collectively do not hold more than 1 of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the
  research report.
- 4. "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this research report.
- "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- 6. "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in
- this report.
  "CEBPL, or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- CEBPL research analyst has not served as an Officer. Director, or employee of the company (ies) covered in the Research report.
- "CEBPL", its research analyst has not been engaged in market making activity for the company(ies) covered in the Research report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. www. https://choiceindia.com/research-listing

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given below

Sr. No.	Particulars	Yes / No
1.	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1 of the company(ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company(ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given below